[
    {
        "id": "osp-12325",
        "type": "article-journal",
        "title": "Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study",
        "author": [
            {
                "family": "Saini",
                "given": "Manu"
            },
            {
                "family": "Bajaj",
                "given": "Mandeep Singh"
            },
            {
                "family": "Pushker",
                "given": "Neelam"
            },
            {
                "family": "Meel",
                "given": "Rachna"
            },
            {
                "family": "Saini",
                "given": "Kulbhushan"
            },
            {
                "family": "Chaurasia",
                "given": "Shweta"
            },
            {
                "family": "Mehta",
                "given": "Aditi"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/evaluation-of-lacrimal-duct-probing-in-adults-with-0-02-and-0-04-mitomycin-c-in-primary-acquired-nasolacrimal-duct-obstruction-a-randomized-comparativ",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2022
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "15",
        "issue": "1",
        "page": "56-60",
        "DOI": "10.4103/ojo.ojo_33_21",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Purpose: The purpose of the study is to evaluate the safety and efficacy of adjunctive use of mitomycin-C (MMC) using two different concentrations 0.2 mg/ml and 0.4 mg/ml for lacrimal duct probing to treat the nasolacrimal duct obstruction (NLDO) in adults.\n\nSubjects and methods: Prospective, an interventional comparative randomized pilot study of lacrimal duct probing conducted in the two study groups 0.02% MMC group (n = 30) and 0.04% MMC group (n = 30) in confirmed primary acquired NLDO of"
    }
]